A world-class specialty pharmaceutical company

Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our portfolio of respiratory products we’re making good progress towards achieving our goal.

Our products

Our novel NIOX® products are used to help improve asthma management around the world, and we market the COPD therapy Tudorza® in the United States.

Our pipeline

Our portfolio includes recently-approved COPD therapy Duaklir®, which we plan to launch in H2 2019, and late-stage nitric oxide product AirNOvent.

About us

We’re a world-class specialty pharmaceutical company focused on asthma and COPD.

Careers

We’re a rapidly growing company with a range of exciting career opportunities.

Investors

Circassia is quoted on AIM under CIR.

Press Releases

More press releases

Share Price

Full share price chart

Annual Report

Read the Annual Report (PDF)